NCT07227597
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07227597
Title A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ISR

Facility Status City State Zip Country Details
Orlando Health Cancer Institute ( Site 0108) RECRUITING Orlando Florida 32806 United States Details
Saint Elizabeth Medical Center Edgewood ( Site 0112) RECRUITING Edgewood Kentucky 41017 United States Details
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101) RECRUITING Hackensack New Jersey 07601 United States Details
The University of Tennessee Medical Center ( Site 0120) RECRUITING Knoxville Tennessee 37920 United States Details
SCRI Oncology Partners ( Site 7000) RECRUITING Nashville Tennessee 37203 United States Details
Beijing Cancer Hospital ( Site 1604) RECRUITING Beijing Beijing Municipality 100142 China Details
Shanghai East Hospital ( Site 1600) RECRUITING Shanghai Shanghai Municipality 200000 China Details
Taizhou Hospital of Zhejiang Province ( Site 1601) RECRUITING Taizhou Zhejiang 317000 China Details
Rambam Health Care Campus ( Site 0602) RECRUITING Haifa 3109601 Israel Details
Sheba Medical Center ( Site 0601) RECRUITING Ramat Gan 5265601 Israel Details
Seoul National University Hospital ( Site 1402) RECRUITING Seoul 03080 South Korea Details
Asan Medical Center ( Site 1404) RECRUITING Seoul 05505 South Korea Details
Samsung Medical Center ( Site 1401) RECRUITING Seoul 06351 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field